PF-562271

Name: PF-562271
Brand: Selleck Chemicals
SKU: S2890
Rating: 5 (78 reviews)

For research use only.

Catalog No.S2890

78 publications

Molecular Weight(MW): 507.49

PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.

Selleck's PF-562271 has been cited by 78 publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

J Clin Invest, 2020, 1;130(5):2422-2434

PubMed: 32250340 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2020, 15

PubMed: 32485098 ( click the link to review the publication )

Cell Rep, 2020, 30(6):1780-1797

PubMed: 32049010 ( click the link to review the publication )

Elife, 2020, 4;9:e50571

PubMed: 32017701 ( click the link to review the publication )

Cell Death Dis, 2020, 14;11(4):230

PubMed: 32286266 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Sci Rep, 2020, 10(1):419

PubMed: 31942012 ( click the link to review the publication )

J Biol Chem, 2020, 12 pii: jbc

PubMed: 32280065 ( click the link to review the publication )

Cell Cycle, 2020, 14:1-13

PubMed: 32286145 ( click the link to review the publication )

Cells, 2020, 9(1)

PubMed: 31905606 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(14):4552-4566

PubMed: 30979745 ( click the link to review the publication )

Sci Signal, 2019, 12(565)

PubMed: 30670633 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):738

PubMed: 31570694 ( click the link to review the publication )

J Biol Chem, 2019, 294(18):7221-7230

PubMed: 30846565 ( click the link to review the publication )

J Tissue Eng Regen Med, 2019, 13(4):625-636

PubMed: 30770650 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(6):1461-1469

PubMed: 31006845 ( click the link to review the publication )

Molecules, 2019, 24(10)

PubMed: 31109130 ( click the link to review the publication )

J Pharm Biomed Anal, 2019, 168:163-173

PubMed: 30807921 ( click the link to review the publication )

Mol Med Rep, 2019, 19(6):4753-4760

PubMed: 31059085 ( click the link to review the publication )

Zygote, 2019, 27(3):173-179

PubMed: 31171046 ( click the link to review the publication )

Cell Rep, 2018, 22(10):2784-2796

PubMed: 29514104 ( click the link to review the publication )
Oncogene, 2018, 37(22):2953-2966

PubMed: 29515233 ( click the link to review the publication )

Oncogene, 2018, 37(23):3166-3182

PubMed: 29545604 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):848

PubMed: 30154481 ( click the link to review the publication )

Cancer Sci, 2018, 109(12):3783-3793

PubMed: 30281878 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(18):e008604

PubMed: 30371220 ( click the link to review the publication )

J Cell Sci, 2018, 131(10)

PubMed: 29678906 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:2190657

PubMed: 30275837 ( click the link to review the publication )

Int J Oncol, 2018, 53(4):1544-1556

PubMed: 30066854 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 10.1038/aps

PubMed: 29417941 ( click the link to review the publication )

Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2325-2333

PubMed: 30106432 ( click the link to review the publication )

Cancer Epidemiol Biomarkers Prev, 2018, 27(7):805-813

PubMed: 29654156 ( click the link to review the publication )

Sci Transl Med, 2017, 9(420)

PubMed: 29237758 ( click the link to review the publication )

Nat Commun, 2017, 8:14122

PubMed: 28098159 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1347-1356

PubMed: 28406574 ( click the link to review the publication )

FEBS J, 2017, 284(17):2856-2869

PubMed: 28665039 ( click the link to review the publication )

Sci Rep, 2017, 7(1):4032

PubMed: 28642549 ( click the link to review the publication )

Mol Carcinog, 2017, 56(12):2558-2565

PubMed: 28667800 ( click the link to review the publication )

Cancer Manag Res, 2017, 9:879-889

PubMed: 29276408 ( click the link to review the publication )

Cell Signal, 2017, 38:1-9

PubMed: 28647573 ( click the link to review the publication )

Oncol Rep, 2017, 38(1):63-70

PubMed: 28560386 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5817-5826

PubMed: 29263678 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2017, 2017:4535326

PubMed: 29234400 ( click the link to review the publication )
Mol Med Rep, 2017, 16(6):8937-8943

PubMed: 28990104 ( click the link to review the publication )

Oncotarget, 2017, 8(43):75102-75113

PubMed: 29088849 ( click the link to review the publication )

Biophys J, 2017, 113(7):1585-1598

PubMed: 28844472 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(2):168-80

PubMed: 26689676 ( click the link to review the publication )

Nat Commun, 2016, 7:10354

PubMed: 26838601 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(23):5851-5863

PubMed: 27220963 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):81

PubMed: 27495308 ( click the link to review the publication )

Oral Oncology, 2016, 10.1016/j.oraloncology.2016.05.010

PubMed: ( click the link to review the publication )

Sci Rep, 2016, 6:36214

PubMed: 27796369 ( click the link to review the publication )

J Biol Chem, 2016, 291(15):8140-9

PubMed: 26865633 ( click the link to review the publication )

Mol Pharmacol, 2016, 89(5):521-40

PubMed: 26895766 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4369-4386

PubMed: 27762562 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 71:62-71

PubMed: 26693891 ( click the link to review the publication )

Oncotarget, 2016, 7(30):48093-48106

PubMed: 27344177 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45186-45198

PubMed: 27286256 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(11):1412-21

PubMed: 26436690 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26274564 ( click the link to review the publication )

Oncogene, 2015, 34(40):5114-27

PubMed: 25639872 ( click the link to review the publication )

Cell Physiol Biochem, 2015, 37(2):515-26

PubMed: 26330161 ( click the link to review the publication )

J Biol Chem, 2015, 290(14):8677-92

PubMed: 25713079 ( click the link to review the publication )

Environ Toxicol Pharmacol, 2015, 39(1):114-24

PubMed: 25481308 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(20):E2595-601

PubMed: 25941386 ( click the link to review the publication )
Oncotarget, 2015, 6(28):25755-69

PubMed: 26342198 ( click the link to review the publication )

Oncotarget, 2015, 6(3):1531-43

PubMed: 25605238 ( click the link to review the publication )

Environ Toxicol Pharm, 2014, 39(1):114-124

PubMed: 25481308 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Int J Clin Exp Pathol, 2013, 6(10):2082-91

PubMed: 24133586 ( click the link to review the publication )

Purity & Quality Control

Choose Selective FAK Inhibitors

Biological Activity

Description

Targets

FAK ^[1] (Cell-free assay)	PYK2 ^[1] (Cell-free assay)	CDK2/CyclinE ^[1] (Cell-free assay)	CDK3/CyclinE ^[1] (Cell-free assay)	CDK1/CyclinB ^[1] (Cell-free assay)	View More
1.5 nM	13 nM	30 nM	47 nM	58 nM	View More

In vitro

PF-562271 binds in the ATP-binding cleft of FAK, forming two of the three “canonical” H-bonds between the inhibitor and main-chain atoms in the kinase hinge region. PF-562271 is potent in an inducible cell-based assay measuring phospho-FAK with IC50 of 5 nM. PF-562271 (3.3 μM) results in G1 arrest of PC3-M cells. ^[1] PF-562271 (1 nM) blocks bFGF-stimulated blood vessel angiogenesis as performed in chicken chorioallantoic membrane assays. PF-262271 potently blocks blood vessel sprouting without detectable changes in vascular leakage. ^[2] PF-562271 (250 nM) results in complete inhibition of collective A431 cell invasion into collagen gels. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
MV-4-11	NWPOdW13T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwMke2OkDPxE1?	M3racXNCVkeHUh?=
SW982	M2fHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFr5eJhKSzVyPUCuN\|I5OiEQvF2=	MX7TRW5ITVJ?
KM12	MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXQOI93UUN3ME2wMlM5PTV5IN88US=>	NYXycmZCW0GQR1XS
COLO-205	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TWSmlEPTB;MD60PFY2QCEQvF2=	NGXJfpdUSU6JRWK=
COLO-829	MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXITWM2OD1yLke1NVc3KM7:TR?=	NUnveoUyW0GQR1XS
MG-63	MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVW0fIhMUUN3ME2wMlgxPjN5IN88US=>	NYXsSFVnW0GQR1XS
IGROV-1	NUTKdZRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoeyTWM2OD1yLkixNFM5KM7:TR?=	M3faenNCVkeHUh?=
NCI-H650	Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13KVWlEPTB;MD64N\|E2PCEQvF2=	NUPLPYx[W0GQR1XS
RT-112	NVHRTWYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHn6WnZKSzVyPUCuPVg1PiEQvF2=	NF75fJBUSU6JRWK=
BCPAP	Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHmTWM2OD1zLkCxNlg5KM7:TR?=	NVL4TmNMW0GQR1XS
ALL-PO	M13Q[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fxPWlEPTB;MT6wNVU5PCEQvF2=	NEHMNWZUSU6JRWK=
KYSE-270	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkH0TWM2OD1zLkC0O\|E1KM7:TR?=	NXzJUVhCW0GQR1XS
8305C	NVjIXFgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\EW2lEPTB;MT6wPVkxPCEQvF2=	NILMVlNUSU6JRWK=
NCI-H810	MnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXoTWM2OD1zLkGwO\|c3KM7:TR?=	NXK4WnFwW0GQR1XS
CAL-33	MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfHXXk5UUN3ME2xMlEzQTN6IN88US=>	M3\xd3NCVkeHUh?=
AN3-CA	M3Tw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofjTWM2OD1zLkKxPFY4KM7:TR?=	M3jnb3NCVkeHUh?=
NKM-1	M4LGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPuVppKUUN3ME2xMlI4PTB4IN88US=>	MofsV2FPT0WU
BPH-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrvcJFKSzVyPUGuNlg4PjZizszN	MX\TRW5ITVJ?
MES-SA	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rJTmlEPTB;MT6zNFY5OiEQvF2=	NV7WfFZiW0GQR1XS
CAL-62	M3\2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2SzZWlEPTB;MT6zNVkxQSEQvF2=	NIHld45USU6JRWK=
Detroit562	NHLibGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjZeYNKSzVyPUGuN\|UzOjJizszN	M3vpdnNCVkeHUh?=
KYSE-150	NEXrXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXmxepRpUUN3ME2xMlM2OjN4IN88US=>	MmW5V2FPT0WU
SK-UT-1	NXrK[\|Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTFwNES2OFch\|ryP	M3qweHNCVkeHUh?=
HUTU-80	NF3NdVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jYRmlEPTB;MT60OFg5PiEQvF2=	MWPTRW5ITVJ?
SIG-M5	NUDWdFk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rUfGlEPTB;MT60PFM5PyEQvF2=	MVHTRW5ITVJ?
AGS	MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TRVGlEPTB;MT61NlEzPCEQvF2=	MVvTRW5ITVJ?
ST486	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLs[YVKSzVyPUGuOVMzPzhizszN	NWO4VWhOW0GQR1XS
HSC-2	M371Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTFwNUO5OUDPxE1?	NHzrO4hUSU6JRWK=
LCLC-103H	MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfHT3JKSzVyPUGuOVU5OThizszN	MXzTRW5ITVJ?
BC-1	MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPZ[ZRKSzVyPUGuOlE3PjRizszN	MWDTRW5ITVJ?
CGTH-W-1	NYrObmdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1G5fWlEPTB;MT62NVY4QSEQvF2=	NE\RbItUSU6JRWK=
MZ1-PC	Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTFwNkKzNVIh\|ryP	M4XDTXNCVkeHUh?=
SW1710	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTFwNkK2Nlgh\|ryP	NEfpZ3FUSU6JRWK=
EW-13	NVz3fXQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfUTWM2OD1zLk[zOFY3KM7:TR?=	M1Lmb3NCVkeHUh?=
TE-11	MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDkSndKSzVyPUGuOlM2OjJizszN	NF;DW4xUSU6JRWK=
BHY	NVfyXpR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PkXWlEPTB;MT62OVY3OyEQvF2=	MmrJV2FPT0WU
ML-2	MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWH2XpRuUUN3ME2xMlY3QDB{IN88US=>	NGK4O21USU6JRWK=
MEL-JUSO	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYW1OWV2UUN3ME2xMlczQDlzIN88US=>	M1jDd3NCVkeHUh?=
U251	NX\aOlJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTFwN{SwN\|Eh\|ryP	NUnKXmlWW0GQR1XS
MHH-ES-1	NILuboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHySHIxUUN3ME2xMlc6PTZ6IN88US=>	MnX6V2FPT0WU
CAL-85-1	MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHO2WnBKSzVyPUGuPFA1QSEQvF2=	NVTWbINRW0GQR1XS
D-336MG	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTFwOEW2NVQh\|ryP	M3q5SnNCVkeHUh?=
VA-ES-BJ	NVrO[pFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nxV2lEPTB;MT65NFMyPSEQvF2=	NE\kSI1USU6JRWK=
MDA-MB-468	Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDu[VY6UUN3ME2xMlkyOjd{IN88US=>	MkTwV2FPT0WU
MEL-HO	MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvHemtKSzVyPUGuPVc6QTNizszN	MXvTRW5ITVJ?
SW954	NHn6S2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4r0eWlEPTB;Mj6wNFE2OSEQvF2=	NF\LRpNUSU6JRWK=
LB831-BLC	NHz0TodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LpcGlEPTB;Mj6wNFk5QCEQvF2=	MW\TRW5ITVJ?
EW-16	NF7lOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jpV2lEPTB;Mj6wN\|k5OyEQvF2=	M17yUHNCVkeHUh?=
NCI-H460	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTETWM2OD1{LkC0PFM6KM7:TR?=	MWfTRW5ITVJ?
CHP-212	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NET5N\|NKSzVyPUKuNFk2OzlizszN	Mmn5V2FPT0WU
MHH-NB-11	M4S5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlu2TWM2OD1{LkGyPFE5KM7:TR?=	MVrTRW5ITVJ?
DU-4475	NX\vVVVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPHZoJ6UUN3ME2yMlE1PzV7IN88US=>	NEPjZ\|NUSU6JRWK=
ABC-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTJwMkWxPVYh\|ryP	MlPOV2FPT0WU
LOUCY	M2jO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPZO4xKSzVyPUKuNlYyOjhizszN	NXLZellHW0GQR1XS
LC-2-ad	NIX2NYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXhVIdKSzVyPUKuNlY6PjZizszN	MnLrV2FPT0WU
ETK-1	NWnMSGR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTJwMki0OkDPxE1?	NUnYWVI5W0GQR1XS
KYSE-180	NFzIO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLMTWM2OD1{LkK4PFc1KM7:TR?=	NEn2SYhUSU6JRWK=
HOP-92	MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTJwM{C2O\|Mh\|ryP	MUnTRW5ITVJ?
RCC10RGB	MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTJwM{K1NFch\|ryP	NUHlSXdnW0GQR1XS
KASUMI-1	NHv2XGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fTXmlEPTB;Mj6zNlg5KM7:TR?=	MlvCV2FPT0WU
ACN	MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLnTWM2OD1{LkO0O\|Q2KM7:TR?=	M1[5OnNCVkeHUh?=
BxPC-3	NETzNHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{n1c2lEPTB;Mj6zOVQ{PiEQvF2=	MlPsV2FPT0WU
MONO-MAC-6	NWnjVW04T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDuT4IzUUN3ME2yMlQyOjR6IN88US=>	NFj6UFZUSU6JRWK=
CAL-39	M371c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTJwNEG2Nlgh\|ryP	MUHTRW5ITVJ?
CMK	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTJwNEG3PVUh\|ryP	MXnTRW5ITVJ?
MFE-296	NEDXUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTJwNEe3PVIh\|ryP	NEnIfWNUSU6JRWK=
DU-145	M320R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DWUWlEPTB;Mj60PVEyQCEQvF2=	M4nGPHNCVkeHUh?=
MDA-MB-231	NYrhfGc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnw[ZYxUUN3ME2yMlQ6PTd{IN88US=>	NWHJPIREW0GQR1XS
EFO-27	Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXuUJVKSzVyPUKuOVE5QDhizszN	MXfTRW5ITVJ?
SNU-387	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWi2XllFUUN3ME2yMlUzQDJizszN	MYrTRW5ITVJ?
KYSE-410	MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjhTWM2OD1{LkW2OVE4KM7:TR?=	Mnf2V2FPT0WU
NCCIT	M{CxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVKxb5MzUUN3ME2yMlU4OjRizszN	MknqV2FPT0WU
LXF-289	MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInQ[lZKSzVyPUKuOVgzPzNizszN	M{izTnNCVkeHUh?=
HMV-II	NFu4[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHFTWM2OD1{LkW4PVk4KM7:TR?=	Mk\0V2FPT0WU
MOLT-4	NELQWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzKTWM2OD1{Lk[wO\|EzKM7:TR?=	MXrTRW5ITVJ?
KOSC-2	MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXu2RmhLUUN3ME2yMlY{QDd7IN88US=>	MlPSV2FPT0WU
TUR	NFnHfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPw[WhKSzVyPUKuOlU{PjlizszN	MYnTRW5ITVJ?
NCI-H2087	NUL4V2NsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3L6TGlEPTB;Mj63NVY1PiEQvF2=	MWTTRW5ITVJ?
SCC-15	NV7ib2twT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTJwN{WyOVIh\|ryP	MlnDV2FPT0WU
HSC-4	MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTJwN{izPFkh\|ryP	MXTTRW5ITVJ?
G-402	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDDUotxUUN3ME2yMlgyPDR5IN88US=>	M4X2bXNCVkeHUh?=
GP5d	M2jENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\SNWlEPTB;Mj64N\|gzPyEQvF2=	NYTqd3g5W0GQR1XS
IGR-1	NHLLXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTJwOEO5PFch\|ryP	M4r0WHNCVkeHUh?=
SK-PN-DW	NGrE[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTYUFhqUUN3ME2yMlg3OjB2IN88US=>	M1HqXHNCVkeHUh?=
OPM-2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjueplDUUN3ME2yMlg6QTd6IN88US=>	MULTRW5ITVJ?
5637	NWXSOpRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWizNoZOUUN3ME2yMlkzPDN7IN88US=>	MYHTRW5ITVJ?
NCI-H2030	M4mxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjxW3pKSzVyPUKuPVgxOjlizszN	Mn3KV2FPT0WU
SK-LU-1	NWf0V2Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3Oe3BiUUN3ME2yMlk5OzN2IN88US=>	NEXufWVUSU6JRWK=
EW-18	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnyVJlKSzVyPUOuNFU{OiEQvF2=	NGK0UppUSU6JRWK=
786-0	NGf0SpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGS0d\|NKSzVyPUOuNFU4QDRizszN	MorxV2FPT0WU
NCI-H1963	NFjNc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2SyOWlEPTB;Mz6wPFgzPSEQvF2=	MmfWV2FPT0WU
A2780	NIXXe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTzTWM2OD1\|LkGwN\|QyKM7:TR?=	MnjKV2FPT0WU
NCI-H526	MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3idlNKSzVyPUOuNVM6PjFizszN	M4LnVHNCVkeHUh?=
BHT-101	M1T5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTNwMUW3PVgh\|ryP	M3:wd3NCVkeHUh?=
RPMI-7951	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1joZWlEPTB;Mz6yNFE{PyEQvF2=	MXPTRW5ITVJ?
HL-60	Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HQXGlEPTB;Mz6yNVE1KM7:TR?=	MVXTRW5ITVJ?
CTV-1	NYPLbJBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX64WnUxUUN3ME2zMlI2Ozd5IN88US=>	NYLLdIF5W0GQR1XS
IST-SL1	NWTJUmJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTNwMkm0OlUh\|ryP	M4T6V3NCVkeHUh?=
G-401	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTNwMkm4NFgh\|ryP	Mn7vV2FPT0WU
OVCAR-5	NYflN3V[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm[zTWM2OD1\|LkO2N\|UzKM7:TR?=	NUfwWVd1W0GQR1XS
EW-1	MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTNwNEC1OFQh\|ryP	NHixdZdUSU6JRWK=
H4	NGDFNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjvRYQ4UUN3ME2zMlQ4PTZ7IN88US=>	MlvpV2FPT0WU
EM-2	M{PKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHBTWM2OD1\|LkS4Olc1KM7:TR?=	M2f6VnNCVkeHUh?=
RS4-11	MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTNwNEi3NVUh\|ryP	MmDoV2FPT0WU
NOMO-1	NHjS[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXyTI5rUUN3ME2zMlQ6OjB2IN88US=>	M3jSXHNCVkeHUh?=
HCT-116	NVrRN\|lnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfPV2JKSzVyPUOuOVA4OTFizszN	MV;TRW5ITVJ?
CAL-120	M133N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTNwNUezOUDPxE1?	NYfnUlVrW0GQR1XS
CAL-51	NHLLPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PaNmlEPTB;Mz61O\|YyOiEQvF2=	MmDaV2FPT0WU
RVH-421	M2nY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XYc2lEPTB;Mz62NFMyOSEQvF2=	MmS0V2FPT0WU
NCI-H2081	M2f4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTNwNkWyPFgh\|ryP	MmXvV2FPT0WU
SBC-5	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\PVIRKSzVyPUOuOlc5QDJizszN	MnTaV2FPT0WU
RL95-2	NULYSWhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTNwN{G4OlQh\|ryP	NE\HXmJUSU6JRWK=
SW872	M1;NfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrVWWRKSzVyPUOuO\|Y6PThizszN	MoK5V2FPT0WU
VM-CUB-1	NEXPXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVO2SWx4UUN3ME2zMlc4PTFizszN	NYnXN4RWW0GQR1XS
SUP-T1	NFnodY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTNwN{izNkDPxE1?	MUPTRW5ITVJ?
697	NFXoO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE[4XohKSzVyPUOuPFE3PTdizszN	NX3FWGUzW0GQR1XS
DBTRG-05MG	NVrXV3p7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTNwOEG2O\|Yh\|ryP	MYHTRW5ITVJ?
TE-441-T	NWS5TWd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zGZ2lEPTB;Mz64Nlk{KM7:TR?=	MWfTRW5ITVJ?
A204	Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTNwOUC5OVYh\|ryP	MYfTRW5ITVJ?
HCC2998	NYTxSWVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTNwOUS4OFMh\|ryP	MlXwV2FPT0WU
SCC-4	NH;Oe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXNU3dKSzVyPUOuPVU4QDJizszN	M3HiOXNCVkeHUh?=
ACHN	NGP0RVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHnTWM2OD12LkCyN\|ch\|ryP	MYPTRW5ITVJ?
NB1	NVfrR5NUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\a[ZFvUUN3ME20MlA3PjR2IN88US=>	MYPTRW5ITVJ?
PANC-08-13	NXO0[pY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjlSIw5UUN3ME20MlA4PzNizszN	NEjob2FUSU6JRWK=
A4-Fuk	Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnWTWM2OD12LkC3PFYyKM7:TR?=	MYfTRW5ITVJ?
NCI-H747	NFy2SodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\Tc3RKSzVyPUSuNFg3PzRizszN	M33aeHNCVkeHUh?=
G-361	MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fFO2lEPTB;ND6wPVA3KM7:TR?=	MU\TRW5ITVJ?
NCI-H292	NH7ZWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjwWppjUUN3ME20MlA6PDJ7IN88US=>	NHfS[nJUSU6JRWK=
HGC-27	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLHR4NFUUN3ME20MlA6PTR7IN88US=>	M1\1e3NCVkeHUh?=
ATN-1	M1XUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DKV2lEPTB;ND6xNFc4PyEQvF2=	NXv0XFd7W0GQR1XS
RPMI-2650	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LDfGlEPTB;ND6xNlk4PSEQvF2=	M4LudnNCVkeHUh?=
SIMA	MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTRwMUS0JO69VQ>?	NGjQO4pUSU6JRWK=
CA46	NIftVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonITWM2OD12LkG2NVA1KM7:TR?=	MlK1V2FPT0WU
CHL-1	NFfrdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEf2U3BKSzVyPUSuNVg6PjFizszN	MnPsV2FPT0WU
TE-10	MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTRwMkK4PFch\|ryP	NIPNcYtUSU6JRWK=
NCI-H1734	Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTiTWM2OD12LkK2Olk2KM7:TR?=	M37NUXNCVkeHUh?=
DV-90	M1K1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;QWHNMUUN3ME20MlI6Ozl5IN88US=>	M2rGVnNCVkeHUh?=
MOLT-16	NVP0emhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XiSWlEPTB;ND6zNVAyPiEQvF2=	MnvtV2FPT0WU
HuCCT1	NFXacmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTRwM{O3NlMh\|ryP	MmTVV2FPT0WU
A3-KAW	NEXMUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfGcW1CUUN3ME20MlM2PTV{IN88US=>	MVfTRW5ITVJ?
HOS	NF61WllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnsTWM2OD12LkO4OVY4KM7:TR?=	MnvhV2FPT0WU
KS-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7jUmNNUUN3ME20MlQzPDV7IN88US=>	NG\ITXhUSU6JRWK=
SNU-423	NHHhUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nmbGlEPTB;ND60NlY5PSEQvF2=	MoHmV2FPT0WU
BC-3	MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXoTWM2OD12LkSzOFc4KM7:TR?=	MYHTRW5ITVJ?
SCC-9	NUTzUnBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M16yS2lEPTB;ND60OFI6QSEQvF2=	M1rLSXNCVkeHUh?=
C8166	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3BTWM2OD12LkS3O\|U{KM7:TR?=	MnvDV2FPT0WU
NCI-H358	NXXlOpdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TWOGlEPTB;ND60PFU{OiEQvF2=	M16wZ3NCVkeHUh?=
GT3TKB	MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HBXGlEPTB;ND60PFgzOiEQvF2=	MmnjV2FPT0WU
NCI-SNU-1	NYDMPWwzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mle5TWM2OD12LkS5O\|AyKM7:TR?=	MkThV2FPT0WU
Ca9-22	NHrKZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnKTWM2OD12LkW1OVE3KM7:TR?=	M3;k[nNCVkeHUh?=
L-363	M{LvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjMTWM2OD12LkW1PVk3KM7:TR?=	M4L0RnNCVkeHUh?=
Calu-1	NXnTVo5yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrZTWM2OD12LkW4O\|A4KM7:TR?=	MnvBV2FPT0WU
OE19	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTRwNkOxOFUh\|ryP	MnroV2FPT0WU
COR-L23	MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\D[mlEPTB;ND62O\|I5KM7:TR?=	M2XZR3NCVkeHUh?=
A431	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\1fWpKSzVyPUSuOlgzOjhizszN	M2rmSnNCVkeHUh?=
MKN1	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjyZ4xKSzVyPUSuO\|A3PjVizszN	NUT3SI01W0GQR1XS
SH-4	NY\tSWhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fUNmlEPTB;ND63NlY{OyEQvF2=	MnK2V2FPT0WU
SNB75	NVrDfZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXCV4JKSzVyPUSuO\|Q3PiEQvF2=	M{TRPXNCVkeHUh?=
SW780	NGfnVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;MNVFKSzVyPUSuO\|Y5PDlizszN	NIj4UIlUSU6JRWK=
GOTO	NWnH[mk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH30blRKSzVyPUSuO\|kzQTNizszN	MY\TRW5ITVJ?
U-266	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\wO3dDUUN3ME20Mlk1QTF7IN88US=>	NGSzU\|BUSU6JRWK=
KURAMOCHI	NWqwU2szT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\V[2lEPTB;NT6wNlg{PCEQvF2=	NHz0SpRUSU6JRWK=
NMC-G1	NWHo[2VMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXz3NWZVUUN3ME21MlA6OTN7IN88US=>	NFL3W3dUSU6JRWK=
COLO-684	NFjSdYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVX1dpNoUUN3ME21MlI2OzdzIN88US=>	Mly2V2FPT0WU
NTERA-S-cl-D1	Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTVwMkmyNVgh\|ryP	MojSV2FPT0WU
RD	NV3ERZh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojjTWM2OD13LkK5O\|cyKM7:TR?=	NF;6b\|lUSU6JRWK=
A2058	NVLXO2hJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fjemlEPTB;NT6zNFQ{QCEQvF2=	Mn3pV2FPT0WU
NCI-H2009	Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTVwM{C1N\|gh\|ryP	NYPiVYpyW0GQR1XS
8-MG-BA	NYfrfmk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1KxOmlEPTB;NT6zO\|A4PyEQvF2=	MXPTRW5ITVJ?
LC4-1	NUfvS2NkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljYTWM2OD13LkO5N\|A{KM7:TR?=	NUTDRnFGW0GQR1XS
A101D	NXzjPGlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTVwM{m2PFkh\|ryP	MUDTRW5ITVJ?
ES8	MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvwS5NKSzVyPUWuOFE1ODlizszN	NF[4NoxUSU6JRWK=
SF126	NUTqVXVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3S1TWlEPTB;NT60NVQ3PSEQvF2=	NYTWVZR2W0GQR1XS
GDM-1	MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTVwNEG3PFEh\|ryP	NUfMdXRqW0GQR1XS
TE-6	M4jSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXiXoY5UUN3ME21MlQ1PTZ7IN88US=>	M2CycnNCVkeHUh?=
SR	NIizdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfNTWM2OD13LkWzOlQ2KM7:TR?=	MoP2V2FPT0WU
HOP-62	NGe5O\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3riOGlEPTB;NT61Olg5PyEQvF2=	M37je3NCVkeHUh?=
HCC2157	M2js[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTVwNU[4PVYh\|ryP	Ml7BV2FPT0WU
TE-15	MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHmUnBQUUN3ME21MlU4Pzd7IN88US=>	Mn;1V2FPT0WU
BFTC-905	NGHI[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTVwNkC0NlEh\|ryP	NXzjR3lqW0GQR1XS
TE-9	M2LOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLhOFFKSzVyPUWuOlE4QDhizszN	MmT4V2FPT0WU
647-V	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTVwNkKwOFIh\|ryP	NUDOcYcxW0GQR1XS
KG-1	M{T4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYr2fWp5UUN3ME21Mlc1ODB3IN88US=>	MWTTRW5ITVJ?
KYSE-510	NFLwPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;4TWM2OD13Lke5OVgyKM7:TR?=	NG\zfJhUSU6JRWK=
SK-MES-1	NHnJVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLjUJJKSzVyPUWuPFU5QTFizszN	M2L2UnNCVkeHUh?=
OVCAR-3	NEjMZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrWTWM2OD13Lki4NlA3KM7:TR?=	Mn6wV2FPT0WU
LB1047-RCC	MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEniZ\|JKSzVyPUWuPVAyPDhizszN	MXXTRW5ITVJ?
HEL	M1;IeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3BTWM2OD14LkCyNVg5KM7:TR?=	Ml:0V2FPT0WU
KARPAS-45	NYji[pVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDoWYFyUUN3ME22MlA{Pzh5IN88US=>	MmLlV2FPT0WU
NCI-H1304	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3H0d2lEPTB;Nj6xNlQ6PyEQvF2=	NWT3V2hFW0GQR1XS
PC-3	NXT4emZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;qXXVUUUN3ME22MlE{ODd{IN88US=>	MnXtV2FPT0WU
Calu-3	MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE[2fGJKSzVyPU[uNVQ3QDlizszN	Mn\vV2FPT0WU
NCI-H1648	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2G0VmlEPTB;Nj6xOVE3KM7:TR?=	MojDV2FPT0WU
HSC-3	MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\1TWM2OD14LkG3N\|k3KM7:TR?=	Mn65V2FPT0WU
COLO-824	NVfQOlBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\pTWM2OD14LkK3PFY5KM7:TR?=	MnPZV2FPT0WU
COLO-680N	NHvTT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIH3OIFKSzVyPU[uN\|c3OzhizszN	Mn3qV2FPT0WU
SK-NEP-1	MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPXTWM2OD14LkSwN\|Yh\|ryP	NUTafHpYW0GQR1XS
SCC-25	MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXX5ToZ{UUN3ME22MlQzPDl\|IN88US=>	NYfqSIg5W0GQR1XS
SF295	NYLn[npDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzFU2ZiUUN3ME22MlQ1QThizszN	MmjhV2FPT0WU
no-10	NEK4OoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDGRYZKSzVyPU[uOFc5PCEQvF2=	M{SxdnNCVkeHUh?=
NCI-H838	MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTZwNUG3NFMh\|ryP	NFzofmZUSU6JRWK=
M059J	NEnS[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;VcY43UUN3ME22MlU2PjJ3IN88US=>	NED0bGNUSU6JRWK=
Calu-6	NVewUpJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHSVoZTUUN3ME22MlY2PDN3IN88US=>	MnPTV2FPT0WU
TE-12	NHjLNI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHCNG82UUN3ME22MlczOzd5IN88US=>	NX;sOmlIW0GQR1XS
639-V	NFfoT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXvTWM2OD14Lke1NVI4KM7:TR?=	M4S0c3NCVkeHUh?=
ESS-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXi[5RKSzVyPU[uO\|YxPzJizszN	NEfMbGxUSU6JRWK=
C-4-II	NH;LR\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDnU5pZUUN3ME22Mlg{OTF5IN88US=>	MWPTRW5ITVJ?
23132-87	M3LOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjhclRKSzVyPU[uPVA6ODFizszN	NFPiRopUSU6JRWK=
MEG-01	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3we4M2UUN3ME22Mlk{PTR4IN88US=>	NVHs[JhQW0GQR1XS
GI-1	M1GyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYCxOoQ2UUN3ME22Mlk1OzR6IN88US=>	NXH1cItUW0GQR1XS
NCI-H2347	M17LU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTZwOUS3NVUh\|ryP	MXzTRW5ITVJ?
MS-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Wx[mlEPTB;Nj65OVE6OiEQvF2=	NGnqTolUSU6JRWK=
SK-MEL-30	Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1q4OGlEPTB;Nj65OlMyPSEQvF2=	M2T0NnNCVkeHUh?=
YKG-1	M2nxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;4fpdKSzVyPUeuNFI3PzhizszN	MUPTRW5ITVJ?
HT-3	MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzRc5dKSzVyPUeuNFM1QSEQvF2=	MVrTRW5ITVJ?
NCI-H2126	M1Thc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXtToZ7UUN3ME23MlA6PzlzIN88US=>	MYDTRW5ITVJ?
GI-ME-N	NX3pOYloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInRXJFKSzVyPUeuNVY6ODZizszN	M2DjdXNCVkeHUh?=
LB771-HNC	M{f6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4D0NGlEPTB;Nz6xPFA{QCEQvF2=	MWLTRW5ITVJ?
LCLC-97TM1	NFniPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHMTWM2OD15LkKxNlc{KM7:TR?=	M2\UbHNCVkeHUh?=
HO-1-N-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTdwMkSwNlQh\|ryP	MkThV2FPT0WU
HCC1143	NX21VHBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrVN3piUUN3ME23MlM4QDl6IN88US=>	NFzmc2JUSU6JRWK=
HuO9	NXq0WoNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHIfZlKSzVyPUeuOFg4QTRizszN	M2nDb3NCVkeHUh?=
IST-SL2	NGK2cWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTdwNUKyO\|Ih\|ryP	M1rrR3NCVkeHUh?=
MLMA	MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTdwNUS2PFkh\|ryP	NVG2TWNrW0GQR1XS
22RV1	M2nGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnT3TWM2OD15Lk[3PVc2KM7:TR?=	MXrTRW5ITVJ?
ONS-76	M4HGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTdwNkm0NVYh\|ryP	NHH4NlFUSU6JRWK=
ECC12	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PoZmlEPTB;Nz63NlkxOSEQvF2=	M{DqW3NCVkeHUh?=
HT-1080	M3XmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETTWIxKSzVyPUeuO\|g2PTVizszN	NV\tWnBLW0GQR1XS
SF268	M{DSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTdwOEO1OkDPxE1?	NUXFSXpkW0GQR1XS
COLO-800	NGXOOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M363bmlEPTB;Nz65NFY5PSEQvF2=	MmnEV2FPT0WU
BB30-HNC	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnLVG1KSzVyPUeuPVQ2PTNizszN	MXPTRW5ITVJ?
CAKI-1	M3OzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRThwME[1NlEh\|ryP	M3K3fXNCVkeHUh?=
GCIY	NV[2XpZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3VeJVOUUN3ME24MlI{PzF\|IN88US=>	M4i4b3NCVkeHUh?=
MKN28	NHTOVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlT6TWM2OD16LkK0OVk5KM7:TR?=	M2jve3NCVkeHUh?=
IPC-298	MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnKOJg5UUN3ME24MlI4PzB7IN88US=>	NXrieIJ5W0GQR1XS
NCI-H1650	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonOTWM2OD16LkK5NVg2KM7:TR?=	M3TLNnNCVkeHUh?=
KP-N-YS	M4jF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPIZlJKSzVyPUiuNlk{ODhizszN	NVzUcZA{W0GQR1XS
J82	NFXHc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRThwM{SxNlQh\|ryP	MlT2V2FPT0WU
SK-HEP-1	NEL3SY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jMTWlEPTB;OD6zOVczOyEQvF2=	MoHNV2FPT0WU
PANC-03-27	NUKweIRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnX5TWM2OD16LkO2PVIh\|ryP	MVnTRW5ITVJ?
KP-4	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnG5TWM2OD16LkSxPFU{KM7:TR?=	M17kVHNCVkeHUh?=
RERF-LC-MS	NV[yTlRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmq5TWM2OD16LkS4OVk2KM7:TR?=	NVrkUGkxW0GQR1XS
C-33-A	M4jYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYO0e4pmUUN3ME24MlYyPTJ7IN88US=>	MVvTRW5ITVJ?
PA-1	M3j6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIL1dXBKSzVyPUiuOlY3QTRizszN	NVHRZnd6W0GQR1XS
TE-5	MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LWfmlEPTB;OD63NFI6PiEQvF2=	MmnmV2FPT0WU
MHH-PREB-1	M4jh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fJUmlEPTB;OD63N\|ExPyEQvF2=	M3i3SnNCVkeHUh?=
C3A	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRThwN{[1OlEh\|ryP	NEHMWW5USU6JRWK=
SK-OV-3	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7oN2pjUUN3ME24Mlc6Pzd{IN88US=>	M3nLdXNCVkeHUh?=
AM-38	NV36T296T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkOwTWM2OD16LkiwOFM6KM7:TR?=	Mn\JV2FPT0WU
LoVo	M1u1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXZTWM2OD16Lkm1OVY3KM7:TR?=	Mnv4V2FPT0WU
MKN45	M1LKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPoUW1UUUN3ME24Mlk3ODZ\|IN88US=>	NHH1NIJUSU6JRWK=
NH-12	M{DmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLXZYtKSzVyPUmuNFI2PDJizszN	MVrTRW5ITVJ?
CAMA-1	M363T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TQZWlEPTB;OT6wOlAyOiEQvF2=	MWjTRW5ITVJ?
HT-29	M4W2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TEXGlEPTB;OT6xNlM4OyEQvF2=	MUPTRW5ITVJ?
DMS-273	MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4D6PGlEPTB;OT6xNlUh\|ryP	MXHTRW5ITVJ?
NCI-H719	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfOU25KSzVyPUmuNVg{QTFizszN	M{jHPXNCVkeHUh?=
SF539	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXmTWM2OD17LkKxNFk5KM7:TR?=	NHvz[nJUSU6JRWK=
Daoy	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjC[VNKSzVyPUmuNlQyPDNizszN	MUHTRW5ITVJ?
HCC70	NEWyN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY[yR3YyUUN3ME25MlI4OzB7IN88US=>	NGTzbm5USU6JRWK=
MFH-ino	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTlwMkmwNFch\|ryP	M{fTdnNCVkeHUh?=
UACC-62	M2nqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXWxVmpRUUN3ME25MlM4Ojl5IN88US=>	NHe0OYhUSU6JRWK=
C2BBe1	NFTk[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;ofGhPUUN3ME25MlM6PjV{IN88US=>	MYLTRW5ITVJ?
KNS-42	M{fpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LUWWlEPTB;OT60N\|QxPyEQvF2=	NEfnZnRUSU6JRWK=
SK-LMS-1	M2K0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\sUmlvUUN3ME25Mlc2PTN3IN88US=>	MXzTRW5ITVJ?
SK-CO-1	NHv5W\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTlwN{[yN\|Uh\|ryP	MUnTRW5ITVJ?
SN12C	NYnLS45qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnv[4RKSzVyPUmuO\|Y5ODZizszN	NILQR2dUSU6JRWK=
HTC-C3	NFK5ZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nnZWlEPTB;OT63O\|k5PCEQvF2=	M4rBcHNCVkeHUh?=
OVCAR-4	M{DqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUX4NI95UUN3ME25Mlg1QDJ6IN88US=>	NX\OTnBvW0GQR1XS
CHP-126	NUm5WItvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTlwOUOyPUDPxE1?	MWrTRW5ITVJ?
NCI-H716	MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\vUIg4UUN3ME25Mlk{OzJ{IN88US=>	NVPJc3lMW0GQR1XS
U-698-M	NIHuO\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTlwOUm3JO69VQ>?	NX7XcZFOW0GQR1XS
EFO-21	MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\5OZRxUUN3ME2xNE4xODl\|IN88US=>	NH7vd4NUSU6JRWK=
RXF393	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrrZVJCUUN3ME2xNE4yOzl{IN88US=>	M3HLc3NCVkeHUh?=
ChaGo-K-1	Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17rZmlEPTB;MUCuNVc4PiEQvF2=	MoP4V2FPT0WU
SJRH30	Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVraR5dVUUN3ME2xNE4yQDR2IN88US=>	MlLEV2FPT0WU
LU-65	NVziO4pbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonkTWM2OD1zMD6yPVQ{KM7:TR?=	NV;2XlRYW0GQR1XS
OS-RC-2	NU[xdYtrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFiyOmpKSzVyPUGwMlMzOjdizszN	M1ixenNCVkeHUh?=
YT	NH60cVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjhUHFHUUN3ME2xNE41ODBzIN88US=>	M{HWS3NCVkeHUh?=
COLO-679	NHnuVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPTcmRKSzVyPUGwMlQzQDVizszN	NWDUSFdXW0GQR1XS
CAS-1	MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXvc\|lzUUN3ME2xNE41PjB6IN88US=>	M2Hud3NCVkeHUh?=
NCI-H2052	NGP3VVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;Mb\|dGUUN3ME2xNE42OTB3IN88US=>	NVi3UHpYW0GQR1XS
NCI-H2452	M3u3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTFyLk[xPFEh\|ryP	NULHZ\|Z{W0GQR1XS
SW13	NYfBdIo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjhU5VKSzVyPUGwMlY{PzRizszN	M2HONXNCVkeHUh?=
HuP-T4	NXfoXmRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG[2dFlKSzVyPUGwMlcxPjhizszN	NIfEUW1USU6JRWK=
UMC-11	NFPIfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo[xTWM2OD1zMD65N\|c{KM7:TR?=	MkXMV2FPT0WU
EGI-1	NFfJd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HhfGlEPTB;MUCuPVQ2PSEQvF2=	Mn7DV2FPT0WU
JiyoyeP-2003	MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTFzLkC4PVIh\|ryP	M1THbnNCVkeHUh?=
J-RT3-T3-5	M1n5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXpUWRKSzVyPUGxMlEzODlizszN	NHnEWndUSU6JRWK=
DoTc2-4510	MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTFzLkGzPFkh\|ryP	NY\GSWJiW0GQR1XS
HLE	Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TUUmlEPTB;MUGuNlEyQSEQvF2=	MoPaV2FPT0WU
SW626	NXTwNVBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHYUYNHUUN3ME2xNU4zQDh7IN88US=>	NXTVS\|gyW0GQR1XS
COR-L105	NUP5[W9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2Wwc2lEPTB;MUGuN\|I{PyEQvF2=	NHfkfFVUSU6JRWK=
ES6	NFjHNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37LZ2lEPTB;MUGuOVc3KM7:TR?=	MUPTRW5ITVJ?
SNU-449	M2j3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTFzLk[wO\|Ih\|ryP	M{\OeXNCVkeHUh?=
GR-ST	NXn6WXdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLrTWM2OD1zMT62NVgyKM7:TR?=	MV;TRW5ITVJ?
BL-41	M1ra[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfkT\|hKSzVyPUGxMlcyPzNizszN	MXrTRW5ITVJ?
GB-1	NYLRPWliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTFzLke2NVkh\|ryP	NEXLToJUSU6JRWK=
COLO-320-HSR	Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTFzLki1NVkh\|ryP	MmPoV2FPT0WU
L-540	NXTYOlFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTFzLki5PUDPxE1?	MlvPV2FPT0WU
NCI-H69	NVTob\|lXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPITWM2OD1zMj6wNVM6KM7:TR?=	MkjzV2FPT0WU
769-P	M3S3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHBTndKSzVyPUGyMlAyQSEQvF2=	MXrTRW5ITVJ?
A172	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nJOGlEPTB;MUKuNVIxPyEQvF2=	M3n0S3NCVkeHUh?=
CAL-27	NYK1Zo9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjte48yUUN3ME2xNk4yOzZ7IN88US=>	MoTEV2FPT0WU
NCI-H1437	NHLPPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTF{LkG0OFch\|ryP	NXPNdJMyW0GQR1XS
REH	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nIbWlEPTB;MUKuNVU4OyEQvF2=	MXnTRW5ITVJ?
KINGS-1	MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVL4UHJNUUN3ME2xNk4{PDJzIN88US=>	NWPKdoJRW0GQR1XS
NCI-H1792	MkXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzpb\|hMUUN3ME2xNk4{QDVzIN88US=>	MlfUV2FPT0WU
SK-MM-2	NEG2OHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DPPWlEPTB;MUKuOFA5PyEQvF2=	Mn;VV2FPT0WU
8505C	NVHzZlhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTlTWM2OD1zMj62NVIh\|ryP	NFHaUHFUSU6JRWK=
HAL-01	MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU[0N5RlUUN3ME2xNk43OTd2IN88US=>	NYX2Zpc3W0GQR1XS
NCI-H2141	NEDVUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUn3WYpUUUN3ME2xNk43PThizszN	NF\qe2tUSU6JRWK=
HCC1806	M2\KWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPIRm5KSzVyPUGyMlY6PTJizszN	NVXhTm14W0GQR1XS
LU-134-A	NIPBb3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLmTVc1UUN3ME2xNk46OyEQvF2=	NGj5[49USU6JRWK=
HT	M1Syemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXCTWM2OD1zMj65OFM4KM7:TR?=	Mlz5V2FPT0WU
OE33	NIe4[\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY[1RXhlUUN3ME2xNk46PDV4IN88US=>	MlrJV2FPT0WU
ES4	MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXkb3NKSzVyPUGyMlk1QDdizszN	NFuxT3RUSU6JRWK=
SW948	NVjpWHN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTkW4JTUUN3ME2xN{4xOTNizszN	MkfZV2FPT0WU
LB2241-RCC	Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTF\|LkG0Olkh\|ryP	NUPRWZpvW0GQR1XS
CCF-STTG1	NXPmW25MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LUcWlEPTB;MUOuOFA{QSEQvF2=	M2fGVXNCVkeHUh?=
RPMI-8402	M3WyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fERWlEPTB;MUOuOVA{OSEQvF2=	M4L0NXNCVkeHUh?=
DEL	NIq4flBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\uelllUUN3ME2xN{42PTB\|IN88US=>	NGDGZ5dUSU6JRWK=
NB5	MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofqTWM2OD1zMz61OVA{KM7:TR?=	M4LNXXNCVkeHUh?=
NUGC-3	NEX1XmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPqZ5E4UUN3ME2xN{44PDV\|IN88US=>	NVn3S2xQW0GQR1XS
CAL-72	M3nJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYj2[VJ[UUN3ME2xOE4yQTB4IN88US=>	M{LkcXNCVkeHUh?=
VMRC-RCZ	Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{f5TmlEPTB;MUSuNlM3KM7:TR?=	MmPSV2FPT0WU
YAPC	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfuV\|dKSzVyPUG0MlI1ODdizszN	Ml;xV2FPT0WU
ES5	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTF2LkK1PVkh\|ryP	NVe1eWRTW0GQR1XS
CAL-12T	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTE[GJvUUN3ME2xOE41OzN4IN88US=>	NX23c2MzW0GQR1XS
GAMG	NFfLV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3pTWM2OD1zND61OVc4KM7:TR?=	Mn\VV2FPT0WU
BT-20	NVLzd2g4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTF2LkmzPFQh\|ryP	Mlv3V2FPT0WU
KALS-1	MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoqyTWM2OD1zNT6wNVU5KM7:TR?=	MUHTRW5ITVJ?
LS-123	M2S5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LCbWlEPTB;MUWuNFE3PSEQvF2=	MmjtV2FPT0WU
LK-2	NE\pT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWr3PGhYUUN3ME2xOU4xQDZ{IN88US=>	MUTTRW5ITVJ?
NCI-H1770	Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHmyPYFKSzVyPUG1MlI5PjhizszN	MmLsV2FPT0WU
MIA-PaCa-2	Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLiUGVmUUN3ME2xOU41OTZ\|IN88US=>	NFjuVY1USU6JRWK=
DB	NHjrUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{K0PGlEPTB;MUWuOlk1OSEQvF2=	MlnHV2FPT0WU
Becker	NFvDUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTkc4xYUUN3ME2xOU45QTJ4IN88US=>	NYnHTm1QW0GQR1XS
HT-144	M3TrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTF3Lkm0PVch\|ryP	M{DQe3NCVkeHUh?=
NCI-H2405	NF\MSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrRbYNSUUN3ME2xOk4zOjF6IN88US=>	Mn[xV2FPT0WU
TK10	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHFTWM2OD1zNj6zO\|QzKM7:TR?=	M1Kxb3NCVkeHUh?=
THP-1	NXryeIJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nRXmlEPTB;MU[uOFY3PSEQvF2=	MYHTRW5ITVJ?
LB373-MEL-D	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2KwO2lEPTB;MU[uOlE{QCEQvF2=	MoXKV2FPT0WU
SJSA-1	MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLTTWM2OD1zNj65NlE6KM7:TR?=	NFL3UYNUSU6JRWK=
EB2	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkP4TWM2OD1zNz63OFI3KM7:TR?=	M13wVnNCVkeHUh?=
MN-60	M1jNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorjTWM2OD1zNz63PVM3KM7:TR?=	NHXkZmtUSU6JRWK=
A253	NIXXPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTF5LkiyOUDPxE1?	M4G3ZnNCVkeHUh?=
CESS	MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTF5LkmzNlYh\|ryP	M2HVdHNCVkeHUh?=
EW-11	M{Lmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4G3S2lEPTB;MUeuPVk2QCEQvF2=	NIXybZFUSU6JRWK=
TE-8	NV3hSmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTF6LkC2Olkh\|ryP	MYnTRW5ITVJ?
UACC-257	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zCd2lEPTB;MUiuNlA3OiEQvF2=	MnP6V2FPT0WU
NCI-H226	M13hc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPyb206UUN3ME2xPE45Ojl7IN88US=>	MU\TRW5ITVJ?
NCI-H748	M{joSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3D[YhKSzVyPUG4Mlg2QDVizszN	NVrmUZRoW0GQR1XS
NCI-H1299	NGjHSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3sdpZtUUN3ME2xPE45QTF6IN88US=>	NYrJfJhRW0GQR1XS
IST-MEL1	MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlO3TWM2OD1zOT6xO\|U1KM7:TR?=	NEi3V41USU6JRWK=
HCC1187	M2C2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTF7LkG3PVYh\|ryP	MWnTRW5ITVJ?
HT-1376	NVvSSpViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvyc4M4UUN3ME2xPU4zODJ7IN88US=>	M4nHWXNCVkeHUh?=
SK-MEL-2	NHSwcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHUUY5jUUN3ME2xPU4zOTV3IN88US=>	MXnTRW5ITVJ?
U031	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVf2SXQzUUN3ME2xPU4zOjF7IN88US=>	MYrTRW5ITVJ?
NCI-H524	MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTF7LkW3NlUh\|ryP	M1L1eXNCVkeHUh?=
KU812	M1KxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrSTWM2OD1zOT61PVQ1KM7:TR?=	M3PycHNCVkeHUh?=
NB10	M3npSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTF7Lk[yOlgh\|ryP	NXLReVBHW0GQR1XS
NOS-1	NGjld2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17iOmlEPTB;MkCuNVU4PyEQvF2=	MYXTRW5ITVJ?
EW-7	M3jnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX6we4xDUUN3ME2yNE4yPjJ6IN88US=>	M4OzOHNCVkeHUh?=
Raji	M3uyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\JTWM2OD1{MD6yOVY5KM7:TR?=	NV7Te4xKW0GQR1XS
LB2518-MEL	M12zVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXRPI1rUUN3ME2yNE4{QTV\|IN88US=>	NXrJSJRKW0GQR1XS
PANC-10-05	NVPsWWZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVK1ToJWUUN3ME2yNE41PjF\|IN88US=>	Ml\IV2FPT0WU
MZ2-MEL	M3\tPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLhWFB1UUN3ME2yNE42QDF2IN88US=>	M{TQUXNCVkeHUh?=
MFE-280	NVjV[3ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;MPJFKSzVyPUKxMlMyQDhizszN	MYjTRW5ITVJ?
RKO	NEm2VHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTJzLkOyNFIh\|ryP	NHHSc5VUSU6JRWK=
KMOE-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrQWFlTUUN3ME2yNU4{Ojh6IN88US=>	MUTTRW5ITVJ?
K5	NVv5dnJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDDfZlJUUN3ME2yNU4{QDl\|IN88US=>	Mk\EV2FPT0WU
NCI-H64	M1XtdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTJzLkS3OVYh\|ryP	MULTRW5ITVJ?
K-562	NWHIXVNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfMXGZPUUN3ME2yNU41QTdzIN88US=>	M2XnW3NCVkeHUh?=
HCE-T	Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTJzLkWwPVQh\|ryP	MV7TRW5ITVJ?
COLO-792	NUnicY1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7NVllGUUN3ME2yNU42QDJ5IN88US=>	NHr5cXBUSU6JRWK=
PFSK-1	NFOzfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGi5ZWxKSzVyPUKxMlY5OzdizszN	M1vI[HNCVkeHUh?=
DOK	MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nwcGlEPTB;MkGuO\|Y5PyEQvF2=	NU\iTHpWW0GQR1XS
NCI-H1882	NXHXenYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPnZXdWUUN3ME2yNU45PTl4IN88US=>	MYDTRW5ITVJ?
KNS-81-FD	NEDVWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zWZmlEPTB;MkGuPFY{OSEQvF2=	MnLrV2FPT0WU
OCUB-M	NEPYTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rxXGlEPTB;MkGuPVY5QCEQvF2=	M13NenNCVkeHUh?=
NCI-H1694	M2PKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XRTGlEPTB;MkGuPVg3OyEQvF2=	NEK5cI9USU6JRWK=
LS-513	M1HY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTPSFlnUUN3ME2yNk4xOzZ5IN88US=>	NUDGWGdIW0GQR1XS
NCI-H2122	NGDDUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTJ{LkG2O\|ch\|ryP	NUn6NlZtW0GQR1XS
IMR-5	Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PoUWlEPTB;MkKuNlg4KM7:TR?=	NEHrSlVUSU6JRWK=
SNU-C2B	NVPaXGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\Bd4pKSzVyPUKyMlY4PDZizszN	MUDTRW5ITVJ?
A498	NET3TlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\sTWM2OD1{Mj64NVc4KM7:TR?=	MlzVV2FPT0WU
NCI-H727	Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTJ{Lki4N\|Yh\|ryP	MYnTRW5ITVJ?
SW1573	NWrnfZRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjWTWM2OD1{Mz6wOlQ3KM7:TR?=	NWX3T2RXW0GQR1XS
RO82-W-1	MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTJ\|LkK1NVEh\|ryP	M3fSZ3NCVkeHUh?=
SKG-IIIa	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHS0[GdKSzVyPUKzMlM2PDZizszN	MofMV2FPT0WU
MC-CAR	MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fuTGlEPTB;MkOuOVE5OyEQvF2=	M4fGVXNCVkeHUh?=
NCI-H446	NVTYdWxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTJ\|Lk[wPVMh\|ryP	MYjTRW5ITVJ?
PC-14	NXnJN5F3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF[ydW1KSzVyPUKzMlY3OjNizszN	MULTRW5ITVJ?
TGBC1TKB	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorzTWM2OD1{Mz63OFYyKM7:TR?=	MmXZV2FPT0WU
EFM-19	NX7RblZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIT4UXdKSzVyPUK0MlE5PDRizszN	NVfPSYFwW0GQR1XS
SK-N-DZ	NYXKVpV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX63XlhOUUN3ME2yOE41QTd5IN88US=>	NXzpNlRxW0GQR1XS
NCI-H661	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzxTWdKSzVyPUK0MlUzOTdizszN	NU[z[5ZSW0GQR1XS
SW1990	M1PoVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\mTJRKSzVyPUK0MlU5QDNizszN	MoPwV2FPT0WU
SW684	MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLkOGo1UUN3ME2yOE44PjJ2IN88US=>	MVLTRW5ITVJ?
Ca-Ski	M2rqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTJ2LkmyN\|ch\|ryP	NVXt[Jg{W0GQR1XS
TGW	NF35TFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTCNHV3UUN3ME2yOU4zOzN5IN88US=>	Mn\tV2FPT0WU
CaR-1	NInOT25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTJ3LkO1O{DPxE1?	NWDic4tIW0GQR1XS
D-247MG	NYnDOmZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTJ3LkS3OFMh\|ryP	MniwV2FPT0WU
CCRF-CEM	NF3M[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrKOHNpUUN3ME2yOU44PDV7IN88US=>	MU\TRW5ITVJ?
CAPAN-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\zUGlEPTB;MkWuO\|UxOSEQvF2=	M1ThXHNCVkeHUh?=
CP50-MEL-B	NXLqbGFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\6fWlEPTB;MkWuPVkxOSEQvF2=	M1z6O3NCVkeHUh?=
FADU	M{TGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHy4OFFKSzVyPUK2MlUyPTJizszN	MmfoV2FPT0WU
Daudi	NXXidVV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2G3XWlEPTB;Mk[uOVE2QCEQvF2=	MVzTRW5ITVJ?
U-87-MG	NFe1eYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlL1TWM2OD1{Nj61N\|A2KM7:TR?=	MWXTRW5ITVJ?
DSH1	NUXUOI1iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmizTWM2OD1{Nj61OFA3KM7:TR?=	NV;RUJZQW0GQR1XS
KYSE-520	NFrKbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nYOmlEPTB;Mk[uOVU2OyEQvF2=	Ml7tV2FPT0WU
HuH-7	NFGzN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3W3TmlEPTB;Mk[uPVA5PiEQvF2=	M3uwUnNCVkeHUh?=
U-2-OS	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nhVmlEPTB;MkeuNFI4OSEQvF2=	M4e2OXNCVkeHUh?=
LU-99A	Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPsTWM2OD1{Nz6xO\|U1KM7:TR?=	NGHX[2FUSU6JRWK=
T98G	NFvO[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTJ5LkG5O\|Mh\|ryP	M3PRcnNCVkeHUh?=
MZ7-mel	NV\wco9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTJ5LkW1OFgh\|ryP	NFjQTWFUSU6JRWK=
SNU-C1	M3PKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFL0U2ZKSzVyPUK3MlY1QTFizszN	MY\TRW5ITVJ?
MDA-MB-175-VII	M3eyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPqTWM2OD1{Nz62PVc2KM7:TR?=	NHjYVHRUSU6JRWK=
HuP-T3	NH3I[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PW[mlEPTB;MkiuNFQ6PSEQvF2=	NVu4UoRrW0GQR1XS
T-24	MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojlTWM2OD1{OD6xPVI2KM7:TR?=	MX\TRW5ITVJ?
HDLM-2	M3m2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3COYhKSzVyPUK4MlI1PTlizszN	MlvxV2FPT0WU
NCI-H1651	NYX3ZmZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTJ6LkK1PVIh\|ryP	NWDzbIpRW0GQR1XS
SK-N-AS	M3znN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;BTWM2OD1{OD6zNVcyKM7:TR?=	M4To[3NCVkeHUh?=
NY	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIWzNHFKSzVyPUK4MlY2PzlizszN	M{LxeXNCVkeHUh?=
D-283MED	NV;tVZlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETnfItKSzVyPUK4Mlg4ODhizszN	NIGzfFlUSU6JRWK=
KLE	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\GTWM2OD1{OD65PVA3KM7:TR?=	M2LxSXNCVkeHUh?=
NCI-H28	NEL4U5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFT4dZFKSzVyPUK5MlAyOiEQvF2=	NIXtWnBUSU6JRWK=
TE-1	NVmxOHV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TLcGlEPTB;MkmuNlE3PyEQvF2=	NVnlS2VXW0GQR1XS
SK-MEL-24	MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XtWmlEPTB;MkmuOVQ3PiEQvF2=	MU\TRW5ITVJ?
CAL-54	NYXXZ4NyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;pXGlEPTB;MkmuOlA1PiEQvF2=	MX7TRW5ITVJ?
A673	NIn0XIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\USWVKSzVyPUK5Mlc{OiEQvF2=	NILDbIxUSU6JRWK=
HEC-1	NVzDdI81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTNyLkCwOVMh\|ryP	NGr5[G9USU6JRWK=
LS-411N	M1LEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfrTWM2OD1\|MD6xOFc2KM7:TR?=	Mn;uV2FPT0WU
SW962	NVXUUYpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTFTWM2OD1\|MD6yOFc4KM7:TR?=	Mnz5V2FPT0WU
OVCAR-8	MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTNyLk[3PVQh\|ryP	M2ewVHNCVkeHUh?=
NCI-H630	NVu0UGkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHuTWM2OD1\|MD64PVU{KM7:TR?=	NWHiU5B[W0GQR1XS
D-263MG	MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLNTWM2OD1\|MT6wOFI1KM7:TR?=	MUTTRW5ITVJ?
NCI-H596	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzDTWM2OD1\|MT6wOlIyKM7:TR?=	NFq1OmhUSU6JRWK=
BB49-HNC	NGO3NVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTNzLkGxNkDPxE1?	MY\TRW5ITVJ?
KYSE-70	MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fRV2lEPTB;M{GuN\|AxQCEQvF2=	MX7TRW5ITVJ?
LAN-6	NI\1Z4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zxdWlEPTB;M{GuOFk6OiEQvF2=	MXHTRW5ITVJ?
NCI-H2228	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnYWGlpUUN3ME2zNU42PjJ3IN88US=>	NYnqPI94W0GQR1XS
SW620	NFi5SVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTNzLk[yPFMh\|ryP	M4DITHNCVkeHUh?=
KM-H2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;LVFJSUUN3ME2zNU44OzB4IN88US=>	MVPTRW5ITVJ?
DJM-1	NVn5Z4pzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLRTWM2OD1\|Mj6xN\|g3KM7:TR?=	MlLqV2FPT0WU
SW48	M3\ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fa[2lEPTB;M{KuN\|gzPSEQvF2=	M3TvRXNCVkeHUh?=
NCI-H1793	MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTN{Lk[xOlMh\|ryP	NF7sNnRUSU6JRWK=
LU-165	M3\hZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYq5PGdrUUN3ME2zN{4xODhizszN	NYXqO2RUW0GQR1XS
EHEB	NV;zT\|BVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHuTWM2OD1\|Mz6wOFk1KM7:TR?=	NED0TGhUSU6JRWK=
NCI-H441	M2jYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTN\|LkKyN\|Uh\|ryP	MlPRV2FPT0WU
LOXIMVI	NHPGeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTXTWM2OD1\|Mz6zOlc6KM7:TR?=	NVPQdXViW0GQR1XS
MC-IXC	M4LJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTN\|LkW2OVUh\|ryP	NISxbWxUSU6JRWK=
NCI-H522	M1PKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7OR41KSzVyPUOzMlY2PCEQvF2=	MnnyV2FPT0WU
IA-LM	NWXie\|RJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorITWM2OD1\|Mz62O\|Q3KM7:TR?=	MmfXV2FPT0WU
NCI-H1417	NEHvWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTxeXVZUUN3ME2zN{46PTh3IN88US=>	NWfISYNVW0GQR1XS
HCC2218	NES1[\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFS4NZpKSzVyPUO1MlIyQDVizszN	M{W3PXNCVkeHUh?=
HC-1	M2fpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG[ybmlKSzVyPUO1MlQxOjRizszN	MkfRV2FPT0WU
HH	NV6xVI1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1m4TGlEPTB;M{WuOFE1OSEQvF2=	M3nyVHNCVkeHUh?=
EFE-184	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHVVndtUUN3ME2zOU43QDJ7IN88US=>	MWrTRW5ITVJ?
NCI-H1355	NVuzOWFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTN3Lke3NVgh\|ryP	NHKxXmFUSU6JRWK=
BV-173	M2L2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfxdXBHUUN3ME2zOU45OjZ2IN88US=>	M4XOb3NCVkeHUh?=
NEC8	Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTN4LkS5NlQh\|ryP	MV;TRW5ITVJ?
SW1463	NVTzU\|VGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTN4Lk[1OlYh\|ryP	NX21XVJDW0GQR1XS
KYSE-140	M2DLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfSW4lWUUN3ME2zOk44Ojl6IN88US=>	NVvwV5NkW0GQR1XS
no-11	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnWcJBKSzVyPUO2Mlg2OzZizszN	M3LJPHNCVkeHUh?=
HCC1937	NHj2XGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTN5LkCxOVQh\|ryP	M1izVHNCVkeHUh?=
LNCaP-Clone-FGC	NYHGT293T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTN5LkG5NFMh\|ryP	NXW4TWcyW0GQR1XS
KARPAS-422	NXGxVZZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrhXWJKSzVyPUO3MlQ1OzFizszN	M2fnXnNCVkeHUh?=
RCM-1	Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DhbWlEPTB;M{euOVM2QCEQvF2=	MV\TRW5ITVJ?
A375	NIDab5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTN5Lke2OFch\|ryP	M2HCOnNCVkeHUh?=
TGBC24TKB	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XMOmlEPTB;M{iuNFI{QSEQvF2=	MYTTRW5ITVJ?
MDA-MB-453	NWDmeIt2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnjN2Y5UUN3ME2zPU4xOjF6IN88US=>	NH7rcJRUSU6JRWK=
Capan-2	NFS4TmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\RTWM2OD1\|OT6wOVA6KM7:TR?=	MlexV2FPT0WU
SW756	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TJO2lEPTB;M{muOVA6OSEQvF2=	MWDTRW5ITVJ?
KU-19-19	NVfPdI5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzONY9KSzVyPUO5MlYzQDJizszN	MUDTRW5ITVJ?
NCI-H2170	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\Id2tPUUN3ME2zPU46QTd5IN88US=>	NE[4bYZUSU6JRWK=
COLO-678	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\3WWlEPTB;NECuOVk2KM7:TR?=	NFy0eJFUSU6JRWK=
PF-382	M3XIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\5O3NVUUN3ME20NE44PDh5IN88US=>	MUHTRW5ITVJ?
OAW-42	M{frU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTR{LkK5OFIh\|ryP	NWDXbI9oW0GQR1XS
LB996-RCC	NILaZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXycXRKSzVyPUSyMlgxODhizszN	NGHyc25USU6JRWK=
SAS	NHnIcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13SWmlEPTB;NEOuOFI5QCEQvF2=	NYXDPYVXW0GQR1XS
MRK-nu-1	NITtdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33OdGlEPTB;NESuO\|QyPCEQvF2=	MXzTRW5ITVJ?
EoL-1-cell	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnNfmhKSzVyPUS0MlkyOzZizszN	MVrTRW5ITVJ?
NCI-H2342	M3XueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTR3LkGxNVch\|ryP	NELvOXRUSU6JRWK=
NCI-H1703	NWTPUlhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnCUoF4UUN3ME20Ok4xPTl{IN88US=>	NUHlZVc{W0GQR1XS
NCI-H187	MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DHZmlEPTB;NE[uNVg3QSEQvF2=	MYLTRW5ITVJ?
CP66-MEL	NX[1dHRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17pemlEPTB;NE[uNlc5QSEQvF2=	NXfZSHpPW0GQR1XS
HCC1569	MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\0d2VRUUN3ME20Ok42QTF5IN88US=>	M3jKdnNCVkeHUh?=
BL-70	NIe0OINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnJVlhKSzVyPUS2Mlc4OzdizszN	M2rxdXNCVkeHUh?=
Saos-2	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUX6N2hjUUN3ME20O{4{OTJ\|IN88US=>	Mmn1V2FPT0WU
LC-1F	Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTR5Lk[xNFUh\|ryP	NHvEXnRUSU6JRWK=
KY821	NHrQZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfKOmozUUN3ME20O{43PDN2IN88US=>	NECzWlVUSU6JRWK=
PSN1	NUn6dYkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXruRlUxUUN3ME20PE4yPDBzIN88US=>	NH3TTZhUSU6JRWK=
RT4	M1jocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTR6LkizO\|ch\|ryP	NFfVU29USU6JRWK=
LS-1034	M2Xxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXyRXUxUUN3ME20PE45QTV2IN88US=>	MULTRW5ITVJ?
NCI-H1395	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1v4RWlEPTB;NEmuNFQ6OiEQvF2=	M1rqSHNCVkeHUh?=
EKVX	NGHicpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rNPGlEPTB;NEmuOlc{OSEQvF2=	M334OnNCVkeHUh?=
IST-MES1	MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\NeppjUUN3ME20PU45QTR2IN88US=>	NHW3c5dUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-FAK / FAK / p-Talin / Talin ; PubMed: 26530902 Cancer Res Dose response of PF-562271 on the phosphorylation of FAK-Y397 or Talin-S425 in PC3-mm2 cells. p-Src / Src / p-paxillin / Paxillin / ICAM-1 ; PubMed: 29417941 Acta Pharmacol Sin MDA-MB-231 cells transfected with FAK-specific siRNAs or treated for 12 h with PF-562271 at the indicated concentrations were subjected to immunoblotting with indicated antibodies.	26530902 29417941
Immunofluorescence	p-FAK; PubMed: 26530902 Cancer Res Immunostaining of PC3-mm2 cells showed that phosphorylated FAK is localized at focal adhesions (inset).	26530902
Growth inhibition assay	Cell viability; PubMed: 28953264 Nutrients MTT assay showed inhibition of cell proliferation and viability in HCT116 (B) and SW480 (D) cell lines treated with resveratrol and/or different concentrations of FAK-Inhibitor (PF-562271: 0.01, 0.1, 1, and 10 µM) cultured in monolayer for 12 h. Data shown are representative of three independent sets of experiments. Values were compared with the control and statistically significant values with p < 0.05 are designated by an asterisk () and p < 0.01 are designated by two asterisks (*).	28953264

In vivo

PF-562271 (< 33 mg/kg p.o.) inhibits FAK phosphorylation in tumors in a dose- and time-dependent manner in U87MG-bearing mice. PF-562271 (50 mg/kg p.o. bid) results in 86% tumor growth inhibition in BxPc3 xenografts mice and 45% tumor growth inhibition in PC3-M xenografts mice. PF-562271 (25 mg/kg, bid) results in 2-fold greater apoptosis in treated tumors in mice bearing H125 lung xenografts. ^[1] PF-562271 (33 mg/kg, p.o.) inhibits extensive movement of the tumor cells over 24 hours in mice. PF-562271 (33 mg/kg, p.o.) results in altered E-cadherin dynamics in mice, which correlates with reduced E-cadherin–dependent collective cell movement. ^[3] PF-562271 (25 mg/kg, p.o. bid) results in 62% tumor growth inhibition in PC3M-luc-C6 subcutaneuous local implant xenograft mouse model. ^[4] PF-562,271 (5 mg/kg, oral) results in significant and similar increases in osteocalcin and cancellous bone parameters and a decrease in tumor growth and signs of bone healing in rats implanted with MDA-MB-231 cells in the tibia. ^[5]

Protocol

Animal Research:^[1]	- Collapse Animal Models: Athymic female mice bearing BxPc3 or PC3-M xenografts. Dosages: 50 mg/kg Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL warmed (197.04 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O For best results, use promptly after mixing.	5 mg/ml

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-562271 SDF

Molecular Weight	507.49
Formula	C₂₁H₂₀F₃N₇O₃S
CAS No.	717907-75-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN(C1=C(CNC2=C(C=NC(=N2)NC3=CC=C4NC(=O)CC4=C3)C(F)(F)F)C=CC=N1)[S](C)(=O)=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

FAK Signaling Pathway Map

Related FAK Products

PND-1186 (VS-4718) ^New

PND-1186 (VS-4718) is a reversible and selective FAK inhibitor with IC50 of 1.5 nM. Phase 1.
PF-431396 ^New

PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively.
Defactinib (VS-6063) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
PF-00562271 Besylate

PF-00562271 Besylate is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
TAE226 (NVP-TAE226)

TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met.
PF-573228

PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3β.
PF-562271 HCl

PF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
Dasatinib

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-562271